ADHD in Saudi Arabia: The System, the Numbers, and the Gaps

The Numbers — and Why One Figure Lies

Most articles about ADHD in the Gulf either ignore Saudi Arabia entirely or reach for a single tidy percentage. Both are mistakes. Saudi Arabia is unusual in this region precisely because it has measured ADHD more than its neighbours have — and the more you measure, the harder it becomes to honour the data with one number. So start with the figure you will see quoted, and then watch it come apart in your hands.

The most thorough synthesis to date is a 2023 systematic review and meta-analysis that pooled 14 Saudi studies covering more than 455,000 people. Its headline estimate for ADHD prevalence in Saudi Arabia is 12.4% — but it reports that figure with a 95% confidence interval running from 5.4% to 26% (Aljadani et al., 2023). Read that band again. The honest reading is not "ADHD affects 12.4% of Saudis." It is "the true rate is somewhere in a range so wide it spans from roughly the global average to one in four." When the interval is that large, the point estimate is the least interesting thing in the sentence. The variability is the story.

Why does the pooled figure land above the global childhood benchmark of about 5.9% (Faraone et al., 2021)? Not because Saudi brains are different, but because the 14 studies underneath it measured very different populations with very different tools — and in epidemiology, the method is the meaning. Screening questionnaires filled in by parents or teachers capture everyone above a symptom threshold, including children who are stressed, exhausted, or simply spirited; full clinical diagnosis, with an interview and impairment criteria, lands far lower. Pool studies that swing between those two approaches and you get a high midpoint with an enormous margin of error. That is exactly what happened here.

You can see the same split in the wider region. A systematic review of 22 studies across Arab countries found ADHD prevalence ranging from as low as 0.5% to as high as 19.6%, with school-aged children clustering around 7.8–11.1% — and, tellingly, rating-scale studies reporting lower figures than clinical-interview ones (Alhraiwil et al., 2015). Inside Saudi Arabia, individual studies scatter the same way: a small cross-sectional study of children in the Makkah region, for instance, used a self-administered online rating scale and produced a far higher figure still — precisely because self-administered online screening inflates rates and cannot stand in for a population diagnosis (Al-Saedi et al., 2023). It is a useful illustration of the method problem, not a prevalence figure to carry around.

So what is the honest summary? ADHD in Saudi Arabia is real, and at least as common as it is anywhere else in the world — the floor of every credible estimate sits at or above the global average. But there is no single trustworthy national number, and anyone who hands you one without its confidence interval is overstating what the evidence can bear. Hold that distinction, because it sets up the genuine paradox of this whole piece. Saudi Arabia has built the region's most developed ADHD system — a national society, a Ministry-of-Health protocol, clinical guidelines — and still, screening comes late, medication options are narrow, and the waiting lists are long: the infrastructure is ahead of the access.

The System Saudi Actually Built

Here is where Saudi Arabia diverges sharply from the rest of the region, and it deserves to be said plainly before any criticism: the Kingdom has built real ADHD infrastructure, and most of its neighbours have not.

It starts with the Saudi ADHD Society (adhd.org.sa), the first specialised ADHD non-profit in the Middle East. It is a licensed national organisation with branches in more than one city, and it runs awareness, training, and family-support work in Arabic — the kind of orientation layer that, in most of the region, simply does not exist. Crucially, it has not stopped at awareness: the Society has been central to producing national, evidence-based clinical practice guidelines for ADHD, the sort of document that turns scattered clinical opinion into a shared standard.

On top of that sits the state itself. The Saudi Ministry of Health publishes a formal "ADHD Across the Life-Span" protocol — and the name matters, because it explicitly extends past childhood to adolescents and adults, a population that most health systems in the region forget entirely. Behind that protocol is a documented national initiative in which Saudi specialists adapted international guidelines (drawing on frameworks like NICE and the American Academy of Pediatrics) to the Saudi context through a structured, peer-reviewed process (AlShehri et al., 2021). This is not a country that has ignored ADHD. It is a country that convened experts, wrote guidelines, adapted them deliberately, and put a protocol on the Ministry's letterhead.

Take that seriously, because it reframes the entire conversation. The problem in Saudi Arabia is not the absence of a system, the way it is in much of the surrounding region. The system exists, and parts of it are genuinely ahead of the curve. The question — the one that defines ADHD here — is whether that system reaches the ordinary person in Jeddah or Abha who suspects something is wrong with how they focus. And on that question, the picture is harder — it is, in the phrase that fits the Kingdom best, infrastructure ahead of access.

Where Access Still Lags

A protocol is a promise. Whether the promise is kept depends on what happens in clinics, classrooms, and waiting rooms — and that is where the gap opens. The most direct evidence comes from the providers themselves. A 2025 survey asked licensed Saudi practitioners about diagnosing and managing ADHD, and their answers are a quiet indictment of the access layer, not the design layer (Alotaibi et al., 2025).

Among the barriers they named: a lack of early screening programmes was the most common, cited by roughly 65% of respondents; limited medication availability came next, at around half; and extended referral waiting lists were flagged by more than 40%. Perhaps most telling for the quality of diagnosis itself: fewer than 60% of these clinicians reported assessing all of the formal diagnostic criteria — meaning a meaningful share were not fully working through the complete checklist a rigorous ADHD diagnosis requires. (This was a small survey of clinicians, not a population study, so read it as a snapshot of provider experience rather than a national audit — but it is a snapshot from inside the system, and it points one way.)

Stack those findings against the previous section and the paradox sharpens. The guidelines exist; the protocol covers the life-span; the Society does its work. But a child whose ADHD is never screened for early does not benefit from a protocol he never enters. An adult on a months-long referral list is not helped by a document she will eventually be assessed against. And a diagnosis made without working through the full criteria is exactly the kind of uneven care a national guideline is supposed to prevent. None of this means the system is a failure — it means the system has been built faster than it has been distributed. That is the difference between having a blueprint and having a building people can actually walk into. This is what infrastructure ahead of access actually looks like — not a slogan, but the measurable shape of the problem.

The Medication Reality

Medication is the area where rumour does the most damage, so this section sticks to what the regulator and the literature actually say — and nothing about how to obtain anything. The single organising fact is that stimulants are controlled substances in Saudi Arabia, dispensed under a restricted prescribing regime, exactly as they are across most of the world.

Within that frame, the registered landscape is more nuanced than the common "you can't get ADHD medication in Saudi Arabia" claim suggests. Methylphenidate — the active ingredient in Ritalin and Concerta — is the primary registered stimulant for ADHD, and the Saudi Food and Drug Authority has continued to approve newer formulations of it. On the amphetamine side, the picture is split: lisdexamfetamine (Vyvanse), an amphetamine prodrug, was approved by the SFDA in 2024 and added to formulary coverage, though it remains comparatively limited and under-prescribed; mixed amphetamine salts — the combination marketed elsewhere as Adderall — are not approved for use in the Kingdom. A narrative review of amphetamine-medication availability describes precisely this: methylphenidate predominates, while amphetamine-based options are restricted and under-used, even as one prodrug has now cleared approval (Alotaibi et al., 2025). So "narrow," not "nonexistent," is the accurate word — and "narrow" is precisely why medication availability shows up as a barrier in the provider survey above.

That is the regulatory landscape, stated as fact — not a workaround. This article will not tell you how to obtain, import, or get around the rules on controlled medication, and you should be wary of anything that does. Whether stimulant treatment is appropriate, which medication, at what dose, and how it is obtained legally are decisions for a licensed Saudi clinician working inside that framework. Full stop.

Stimulants are also not the only path. Non-stimulant medication and behavioural approaches — parent training, structured support, and therapy — are part of standard ADHD care everywhere, and they matter especially where stimulant access is constrained. The honest map of how the options compare, including the things marketed as "natural," is laid out in ADHD medications and natural remedies. For a reader in Saudi Arabia, the bottom line does not change: the regulatory reality is what it is, and your treatment is your clinician's call — never something to source on your own.

Stigma and the Adult Gap

Infrastructure can be built by ministries and societies. The two things slowing it down — stigma and the thinness of adult data — are harder to legislate, because they live in families and in the gaps of the research literature.

Stigma first. In many households a psychiatric label is something to fear and hide rather than investigate — a worry about reputation, about a marriage prospect, about how a child will be seen. That fear is understandable, and naming it is not an accusation; it is a description of a real pressure that keeps people away from assessment and quiet about a diagnosis once they have one. Its effect on the data is direct: under-reporting all the way down. Families hesitate, cases do not reach clinics, clinics do not generate records, and the country's apparent ADHD rate is pulled lower than the reality — which then gets read, circularly, as evidence that it is not much of a problem. Classroom behaviour plays its part too: a child who cannot sit still, blurts out answers, and forgets the homework written on the board ten minutes ago is easily read as lazy or badly raised rather than as a child with a neurodevelopmental condition. That "lazy" label rests on a genuine, dopamine-driven difficulty with boring, unrewarding tasks — explained in the ADHD dopamine deficit — and it is not a failure of will.

Then there is the adult gap, which Saudi Arabia's own life-span protocol implicitly acknowledges even as the data struggles to keep up. Almost all of the prevalence research is on children; published adult figures are thin, and women — the most under-recognised group of all — are barely represented. Adults who suspect ADHD are sometimes told flatly that it is a childhood condition they have outgrown, and women hear a particular version: that they "can't have ADHD," because the picture in too many clinicians' heads is still a hyperactive young boy. The anxiety or low mood that so often travels with untreated ADHD then gets named as the whole story. The overlap and the distinction between ADHD and the conditions it is mistaken for is laid out in ADHD and its look-alikes; the specific way it is missed in women, in how ADHD shows up in women; and the long arc of being recognised only in adulthood, in ADHD and late diagnosis.

One symptom of the access gap deserves careful, unsensational mention. A study of medical students across three Riyadh universities found that a small minority — about 2.5% — reported using stimulants without a prescription, most often to study for longer (Alrakaf et al., 2020). That is not a story about an epidemic, and it is not proof of anything on its own. But it sits at the intersection of high academic pressure, real attention difficulties, and a diagnostic pathway that many people find slow or hard to enter — which is exactly the terrain a well-distributed system is meant to cover. It is one more reason the access half of "infrastructure ahead of access" is the half that needs the work.

Where to Get Help

If you have read this far because the description fits — you, your child, or someone you love — here is the grounded, non-promotional version of what to do, and the good news is that Saudi Arabia gives you more real starting points than most of the region.

One thing this article will not do is hand you a self-diagnosis. If the pattern here rings true, that is a reason to seek a proper assessment, not a verdict in itself. The point of laying out the data, the system, the medication reality, and the access gaps is so that you walk into that appointment informed — knowing what to ask, what a good assessment involves, and that your experience is real and worth taking seriously. Having a protocol isn't the same as having a system that reaches you — so part of getting help, in a country this far along, is knowing how to reach into the system yourself.

Where Zalfol Fits

Everything above describes a country that has done the hard institutional work — a society, a protocol, guidelines — and still leaves the individual waiting: for an early screening that never came, for a referral at the end of a long list, for a clinic that may be a city away. Zalfol cannot change the epidemiology or the regulations, and it does not pretend to. What it can be is the part of the picture that the infrastructure has not yet reached: the support available today, in Arabic, with no waiting list — for the long stretch before access, alongside it, or when a clinic is simply out of reach. Here is the narrow, honest place it helps.

• The Heart is where you turn a vague "something is wrong with how I focus" into something a clinician can actually use. Log your patterns — the days that fell apart, the tasks that wouldn't start, the moods that swung — and over a few weeks you build a real record of your own experience instead of reconstructing it from memory in a ten-minute appointment. That record is exactly what helps an assessment go well, especially if you are an adult or a woman walking in against the stereotype. The Heart box is not therapy. It is a log. No analysis, no advice — just an honest account you can point to.
• Goldfish is execution help that doesn't require a diagnosis to begin. You don't need a prescription or a clinic to lower the bar to a single, visible action: one task, full screen, start. On the days the workload feels impossible — diagnosed or not, medicated or not — shrinking the world down to one thing is how you keep moving without grinding yourself into shame.
• CEO Mode is the structure for a brain the system was slow to catch. If you spent years being told you were lazy or scattered, you may never have been handed a way to plan that fits how your attention actually works. CEO Mode is that scaffolding — turning a month of vague intentions into a few clear objectives and the small steps beneath them, externalised so your brain doesn't have to hold it all at once.
• Dump is the relief valve for an overloaded mind. When everything is swirling at once — and an under-supported ADHD brain in a demanding life produces a lot of swirl — you empty it all onto the screen, unfiltered and unstructured, and let the system help sort it afterward. It is the simplest, most immediate thing here, and often the first that helps.

None of this is a treatment, and it is not meant to be. Zalfol is a cognitive tool, not a medical treatment. The diagnosis belongs to a clinician and the medication belongs to the regulated system this article described. What a cognitive system can do is hold the noticing, the planning, and the starting steady — in your language, on your worst days, without an appointment — for the long interval the infrastructure has not yet closed. That is the entire idea behind the way it is built. Zalfol works with the wiring. Not against it.

So take the data seriously, and take yourself seriously with it. ADHD in Saudi Arabia is not a rare condition and not a foreign import — it is a common one in a country that has, to its real credit, started building the system to meet it. The single line worth carrying out of all of this is the one the evidence keeps pointing back to: infrastructure ahead of access — and closing that gap is the whole task.

Frequently Asked Questions

Sources

1. Aljadani, A. H., Alshammari, T. S., Sadaqir, R. I., et al. (2023). Prevalence and Risk Factors of Attention Deficit-Hyperactivity Disorder in the Saudi Population: A Systematic Review and Meta-analysis. Saudi Journal of Medicine & Medical Sciences, 11(2), 126–134. Pooled prevalence 12.4% (95% CI 5.4–26%), 14 studies, N=455,334. PMC10211419
2. Alhraiwil, N. J., Ali, A., Househ, M. S., Al-Shehri, A. M., & El-Metwally, A. A. (2015). Systematic review of the epidemiology of attention deficit hyperactivity disorder in Arab countries. Neurosciences (Riyadh), 20(2), 137–144. PMC4727626
3. Al-Saedi, Z. S., Alharbi, A. M., Nmnkany, A. M., et al. (2023). Prevalence of ADHD Among Children in Makkah Region, Saudi Arabia. Cureus, 15(3), e35967. Small cross-sectional online screening study (n=387) — cited as an illustration of screening-method inflation, not a prevalence figure. PMC10082936 (PMID 37041915)
4. AlShehri, A. M., et al. (2021). Adapting evidence-based clinical practice guidelines for people with attention deficit hyperactivity disorder in Saudi Arabia: process and outputs of a national initiative. Child and Adolescent Psychiatry and Mental Health. National CPG adaptation (NICE/AAP-derived). PMC7871371
5. Saudi Ministry of Health. MOH Protocol for ADHD Across the Life-Span. Ministry of Health, Kingdom of Saudi Arabia. moh.gov.sa (PDF)
6. Saudi ADHD Society. National non-profit; awareness, training, family support, and clinical practice guideline work. adhd.org.sa
7. Alotaibi, M. M., Alrashdi, N. Z., Alanazi, S. A., et al. (2025). Diagnosis and Management of ADHD: A Practitioner's Perspective. Journal of Clinical Medicine, 14(9), 2874. Survey of licensed Saudi practitioners (N=43): no early screening 65.1%, limited medication availability 51.2%, extended referral waits 44.2%; 55.8% assessed all DSM-5 criteria. PMC12072822
8. Alotaibi, M. M., Alrashdi, N. Z., Alzubaidi, B., et al. (2025). Challenges in amphetamine medication availability for individuals with ADHD: a narrative review. Frontiers in Psychiatry. Methylphenidate predominant; lisdexamfetamine SFDA-approved (2024) but under-prescribed; amphetamine options restricted. PMC12326170
9. Alrakaf, F. A., Binyousef, F. H., Altammami, A. F., et al. (2020). Illicit Stimulant Use among Medical Students in Riyadh, Saudi Arabia. Cureus, 12(1), e6688. N=1,177; 2.46% reported illicit stimulant use, most often to prolong study time. PMC7026881
10. Faraone, S. V., et al. (2021). The World Federation of ADHD International Consensus Statement: 208 Evidence-based Conclusions about the Disorder. Neuroscience & Biobehavioral Reviews, 128, 789–818. Global childhood prevalence ~5.9%. PMC8328933